FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients - Active Path in OR and WA

Take our online depression self-assessment

BURLINGTON, Mass. Aug. 18, 2021 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) allowing the Company to market its Deep Transcranial Magnetic Stimulation (Deep TMS™) System for the reduction of comorbid anxiety symptoms in adult patients with depression, also known as anxious depression.

“This clearance expands upon BrainsWay’s depression indication, and represents yet another in a series of firsts for the Company,” said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. “Many patients suffering from major depression experience anxiety symptoms. This most recent regulatory achievement further establishes BrainsWay’s leadership position at the forefront of bringing transformative solutions to advance patient wellness.”

For more information, visit BrainsWay’s website: https://www.brainsway.com/news_events/fda-clears-brainsway-deep-tms-system-for-decreasing-anxiety-symptoms-in-depressed-patients/

Recent Posts

10 Tips to Relieve Holiday Stress

10 Tips to Relieve Holiday Stress

Many of us find the holidays bring as much stress as they do joy. But there are ways to ease through the season. According to a new poll from the American Psychiatric Association (APA), 31% of...

read more